Premium
Successful treatment of secondary graft failure following unrelated cord blood transplant with hematopoietic growth factors in a pediatric patient with F anconi anemia
Author(s) -
Buchbinder David,
Hsieh Loan,
Mahajerin Arash,
Puthenveetil Geetha,
Soni Amit,
Nugent Diane
Publication year - 2015
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12564
Subject(s) - medicine , fanconi anemia , savior sibling , anemia , bone marrow failure , ganciclovir , cord blood , aplastic anemia , surgery , romiplostim , haematopoiesis , transplantation , bone marrow , hematopoietic stem cell transplantation , immunology , stem cell , dna repair , biochemistry , chemistry , genetics , virus , biology , human cytomegalovirus , gene , thrombopoietin
Graft failure following allogeneic HCT in Fanconi anemia is associated with significant mortality. Retransplantation may be considered; however, the limited toxicity profile of HGF s also makes them an option for the treatment of graft failure. We describe a five‐yr‐old female diagnosed with Fanconi anemia and marrow failure treated with HCT . The course was complicated by secondary graft failure treated successfully with HGF s including G ‐ CSF , EPO , and romiplostim. The outcome could be related to the intervention, but could also be the natural course of recovery, including recovering from a recent CMV infection treated with ganciclovir. We found the use of HGF s to be an effective and safe alternative to the potential complications as well as morbidity and mortality associated with the use of retransplantation.